Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia

Canada, 7 July 2021, Huynh et al Nature

Summary

Report on 5 patients with VITT following a single dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca COVID-19 vaccine, AstraZeneca; COVISHIELD, Verity Pharmaceuticals and Serum Institute of India) and subsequently developed thrombocytopaenia and thrombosis; the mean age of patients was 44 years (range, 35–72 years) and 2 out of 5 (40%) were female. The time from first dose of the ChAdOx1 nCoV-19 vaccine to sample collection was 14–40 days (mean, 28 days). All samples from patients with VITT (hereafter, VITT samples) had antibodies against PF4 (mean optical density (OD), 2.71; range, 0.763–3.347).

Download PDF

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s